BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 15329912)

  • 21. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
    Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
    J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.
    Santi M; Mena H; Wong K; Koeller K; Olsen C; Rushing EJ
    Cancer; 2003 Aug; 98(3):554-61. PubMed ID: 12879473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy in supratentorial gliomas. A study of 821 cases.
    Heesters M; Molenaar W; Go GK
    Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
    J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
    Prayson RA; Mohan DS; Song P; Suh JH
    Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
    McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
    Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pleomorphic xanthoastrocytoma: what do we really know about it?
    Giannini C; Scheithauer BW; Burger PC; Brat DJ; Wollan PC; Lach B; O'Neill BP
    Cancer; 1999 May; 85(9):2033-45. PubMed ID: 10223246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Supra-tentorial low-grade astrocytomas in adults. Prognostic factors and therapeutic indications. Apropos of a series of 141 patients].
    Loiseau H; Bousquet P; Rivel J; Vital C; Kantor G; Rougier A; Dartigues JF; Cohadon F
    Neurochirurgie; 1995; 41(1):38-50. PubMed ID: 7651570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression.
    Mineo TC; Ambrogi V; Mineo D; Baldi A
    Cancer; 2005 Nov; 104(10):2063-71. PubMed ID: 16206298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
    Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Mariani L; Siegenthaler P; Guzman R; Friedrich D; Fathi AR; Ozdoba C; Weis J; Ballinari P; Seiler RW
    Acta Neurochir (Wien); 2004 May; 146(5):441-8. PubMed ID: 15118879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.